anti-Fibrin Degradation Product, D-Dimer antibody product blog
Tags: Antibody; Monoclonal Antibody; Fibrin Degradation Product, D-Dimer; anti-Fibrin Degradation Product, D-Dimer antibody;
The Fibrin Degradation Product, D-Dimer n/a (Catalog #MBS631549) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Fibrin Degradation Product, D-Dimer reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s Fibrin Degradation Product, D-Dimer can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA), Western Blot (WB).Suitable for use in ELISA and Western Blot.
Dilution: Sandwich ELISA: Plasma samples should be diluted with 10mM Tris-HCl buffer, pH 7.5, 1M sodium chloride, 0.1% Tween-20. To avoid non-specific binding, the final sodium chloride concentration in plasma samples should be 0.5M. Researchers should empirically determine the suitability of the Fibrin Degradation Product, D-Dimer n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Human D-dimer (DD), a specific degradation product of cross-linked fibrin, is released into the bloodstream during clot breakdown. It is used as an indicator of blood clots, venous thromboses or pulmonary embolisms.
Immunogen: Homogenized fibrin clot. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Fibrin Degradation Product, D-Dimer are readily searchable from our website. Different antibodies against the same target such as Fibrin Degradation Product, D-Dimer may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.